In re Generic Pharm. Pricing Antitrust LitigDate Filed: August 15, 2016
District Court: Eastern District of Pennsylvania – MDL No. 525; MDL No. 2724
Nature of Suit: Antitrust
Defendant Type: Pharma
Plaintiff Type: State
Court Document: https://www.bloomberglaw.com/public/desktop/document/In_re_Genenric_Drug_Pricing_Antitrust_Litig_No_MDL_2724_2018_BL_1?1528398083; http://www.paed.uscourts.gov/documents2/mdl/mdl2724
Plaintiffs are attorney generals from over 40 states, Puerto Rico, and the District of Columbia that filed an antitrust enforcement action against six pharmaceutical manufacturers in the District of Connecticut relating to eighteen pharmaceutical products. Plaintiffs assert claims for price fixing of generic drugs in violation of the Sherman Act and/or state antitrust laws on behalf of overlapping putative nationwide classes of direct or indirect purchasers of generic pharmaceuticals. Defendants are alleged to have effectuated the alleged conspiracy through direct company-to-company contacts and through joint activities undertaken through trade associations, in particular meetings of the Generic Pharmaceutical Association. The allegations stem from the same government investigation into anticompetitive conduct in the generic pharmaceuticals industry.